Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...
Management of newly diagnosed acute myeloid leukemia (AML) in patients deemed unfit for intensive chemotherapy is undergoing ...
The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...
Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...
HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates ...
—According to these findings, unrelated peripheral blood stem cell transplantation may be better for adult patients with acute myeloid leukemia compared to unrelated bone marrow stem cell ...
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback